CiNii 図書 - Camptothecins in cancer therapy

A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.

Part I: Biochemistry, Pharmacology, and Chemistry Mechanism of Action of Topoisomerase 1 Poisons Leroy F. Liu and Shyamal D. Desai Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage Alex B. Burgin, Jr., Michael D. Feese, Bart L. Staker, and Lance Stewart Inhibitors of Topoisomerase I Function Sidney M. Hecht Cytotoxic Mechanisms of the Topoisomerase 1 Inhibitors Yves G. Pommier, Juana Barcelo, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter J. Houghton Mechanisms of Resistance to Camptothecins Zeshaan A. Rasheed and Eric H. Rubin Recent Advances in Camptothecin Drug Design and Delivery Strategies Thomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus Part II: Clinical Perspectives Clinical Experience With 9-Aminocamptothecin: Lessons for New Drug Development Chris H. Takimoto Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin) Hilary Hewes, Judith A. Smith, and Claire Verschraegen Irinotecan: Current Clinical Status and Pharmacological Aspects Laurent P. Rivory Clinical Experience With Topotecan Aimee K. Bence and Val R. Adams The Clinical Development of Lurtotecan: Experience With Water-Soluble and Liposomal Forms Keith T. Flaherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer Preclinical and Clinical Development of Exatecan (DX-8951f): A Hexacyclic Camptothecin Analog Eric K. Rowinsky Camptothecins in the Treatment of Primary Brain Tumors Clinton F. Stewart,Markos Leggas, and Henry S. Friedman Camptothecins in the Treatment of Lung Cancer Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler Use of Camptothecins in the Treatment of Leukemia and Related Disorders Benjamin M. F. Mow and Scott H. Kaufmann Index

巻冊次: : e-ISBN ISBN 9781592598663

内容説明

The text provides an up to the minute summary of what is known today about the biochemistry and pharmacology of the camptothecins. The chapter that covers this subject includes a discussion of the mechanism of action of topoisomerase I, and a review of the means by which camptothecins poison this enzyme. The use of animal models in defining the anticancer potential of camptothecins and a discussion of camptothecin resistance is included. Part two of the text is devoted to a review of new analogue development as well as drug delivery issues that are aimed at optimizing the anticancer activities of camptothecins. In the last section of the book the clinical perspective is presented. The authors have included current summaries on each of the members of the camptothecin families that have been studied in the clinic. Along with these reviews discussions of the potential use of camptothecins in a variety of different cancers has been included.

Part I. Biochemistry, Pharmacology, and Chemistry
Mechanism of Action of Topoisomerase I Poisons
Leroy F. Liu and Shyamal D. Desai
Crystallographic Insight into the Mechanism of Drug-Induced Topoisomerase I DNA damage
Alex B. Burgin, Jr., Bart L. Staker, and Lance Stewart
Inhibitors of Topoisomerase I Function
Sidney M. Hecht
Cytotoxic Mechanisms of the Topoisomerase I Inhibitors
Yves Pommier, Juana Barcelo, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao
Biochemical and Genetic Analyses of DNA Topoisomerase I-Mediated DNA Damage
Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti
Preclinical Models for Evaluating Topoisomerase-I Targeted Drugs
Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter Houghton
Mechanisms of Resistance to Camptothecins
Zeshaan A. Rasheed and Eric H. Rubin
Recent Advances in Camptothecin Drug Design and Delivery Strategies
Thomas G Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus
Part II. Clinical Perspectives
Clinical Experience with 9-Aminocamptothecin: Lessons for New Drug Development
Chris H. Takimoto
Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)
Hilary Hewes, Judith A. Smith, and Claire Verschraegen
Irinotecan: Current Clinical Status and Pharmacological Aspects
Laurent P. Rivory
Clinical Experience with Topotecan
Aimee K. Bence and Val R. Adams
The Clinical Development of Lurtotecan: Experience with Water-Soluble and Liposomal Forms
Keith T. Flatherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer
Preclinical and Clinical Development of DX-8951f (Exatecan Mesylate), a Hexacyclic Camptothecin Analog
Eric K. Rowinsky
Camptothecins in the Treatment of Primary Brain Tumors
Clinton F. Stewart, Markos Leggas, and Henry S. Friedman
Camptothecins in the Treatment of Lung Cancer
Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler
'Use of Camptothecins in the Treatment of Leukemia and Related Disorders
Bejamin M. F. Mow and Scott H. Kaufmann

「Nielsen BookData」より

Camptothecins in cancer therapy

著者

書誌事項

大学図書館所蔵全3件

この図書・雑誌をさがす

注記

内容説明・目次

関連文献： 1件中 1-1を表示

詳細情報

書き出し